10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

PRPF31 Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP14542b

Specification

PRPF31 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession Q8WWY3

PRPF31 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 26121

Other Names
U4/U6 small nuclear ribonucleoprotein Prp31, Pre-mRNA-processing factor 31, Serologically defined breast cancer antigen NY-BR-99, U4/U6 snRNP 61 kDa protein, Protein 61K, hPrp31, PRPF31, PRP31

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PRPF31 Antibody (C-term) Blocking Peptide - Protein Information

Name PRPF31

Synonyms PRP31

Function
Involved in pre-mRNA splicing as component of the spliceosome (PubMed:11867543, PubMed:28781166). Required for the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome (PubMed:11867543).

Cellular Location
Nucleus. Nucleus speckle. Nucleus, Cajal body. Note=Predominantly found in speckles and in Cajal bodies.

Tissue Location
Ubiquitously expressed.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

PRPF31 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

PRPF31 Antibody (C-term) Blocking Peptide - Images

PRPF31 Antibody (C-term) Blocking Peptide - Background

This gene encodes a component of the spliceosome complexand is one of several retinitis pigmentosa-causing genes. When thegene product is added to the spliceosome complex, activationoccurs.

PRPF31 Antibody (C-term) Blocking Peptide - References

Schneider, M., et al. Nat. Struct. Mol. Biol. 17(2):216-221(2010)Bujakowska, K., et al. Invest. Ophthalmol. Vis. Sci. 50(12):5927-5933(2009)Potkin, S.G., et al. PLoS ONE 4 (8), E6501 (2009) :Liu, S., et al. Science 316(5821):115-120(2007)Sullivan, L.S., et al. Invest. Ophthalmol. Vis. Sci. 47(10):4579-4588(2006)